LeBlanc Annie, Herrin Jeph, Williams Mark D, Inselman Jonathan W, Branda Megan E, Shah Nilay D, Heim Emma M, Dick Sara R, Linzer Mark, Boehm Deborah H, Dall-Winther Kristen M, Matthews Marc R, Yost Kathleen J, Shepel Kathryn K, Montori Victor M
Division of Health Care Policy and Research, Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota2Knowledge and Evaluation Research Unit, Mayo Clinic, Rochester, Minnesota3Robert D. and Patricia E. Kern Mayo Clinic Center for the Scie.
Yale University School of Medicine, New Haven, Connecticut5Health Research & Educational Trust, Chicago, Illinois.
JAMA Intern Med. 2015 Nov;175(11):1761-70. doi: 10.1001/jamainternmed.2015.5214.
For antidepressants, the translation of evidence of comparative effectiveness into practice is suboptimal. This deficit directly affects outcomes and quality of care for patients with depression. To overcome this problem, we developed the Depression Medication Choice (DMC) encounter decision aid, designed to help patients and clinicians consider the available antidepressants and the extent to which they improved depression and other issues important to patients.
Estimate the effect of DMC on quality of the decision-making process and depression outcomes.
DESIGN, SETTING, AND PARTICIPANTS: We conducted a cluster randomized trial of adults with moderate to severe depression considering treatment with an antidepressant. Primary care practices in 10 rural, suburban, and urban primary care practices across Minnesota and Wisconsin were randomly allocated to treatment of depression with or without use of the DMC decision aid.
Depression Medication Choice, a series of cards, each highlighting the effect of the available options on an issue of importance to patients for use during face-to-face consultations.
Decision-making quality as judged by patient knowledge and involvement in decision making, patient and clinician decisional comfort (Decisional Conflict Scale) and satisfaction, encounter duration, medication adherence, depression symptoms, and the Patient Health Questionnaire for depression (PHQ-9).
We enrolled 117 clinicians and 301 patients (67% women; mean [SD] age, 44 [15] years; mean [SD] PHQ-9 score, 15 [4]) into the trial. Compared with usual care (UC), use of DMC significantly improved patients' decisional comfort (DMC, 80% vs UC, 75%; P = .02), knowledge (DMC, 65% vs UC, 56%; P = .03), satisfaction (risk ratio [RR], from 1.25 [P = .81] to RR, 2.4 [P = .002] depending on satisfaction domain), and involvement (DMC, 47% vs UC, 33%; P<.001). It also improved clinicians' decisional comfort (DMC, 80% vs UC, 68%; P < .001) and satisfaction (RR, 1.64; P = .02). There were no differences in encounter duration, medication adherence, or improvement of depression control between arms.
The DMC decision aid helped primary care clinicians and patients with moderate to severe depression select antidepressants together, improving the decision-making process without extending the visit. On the other hand, DMC had no discernible effect on medication adherence or depression outcomes. By translating comparative effectiveness into patient-centered care, use of DMC improved the quality of primary care for patients with depression.
clinicaltrials.gov Identifier: NCT01502891.
对于抗抑郁药而言,将比较疗效证据转化为实际应用的情况并不理想。这一不足直接影响抑郁症患者的治疗结果和护理质量。为克服这一问题,我们开发了抑郁症药物选择(DMC)会诊决策辅助工具,旨在帮助患者和临床医生考虑现有的抗抑郁药以及它们改善抑郁症和其他对患者重要问题的程度。
评估DMC对决策过程质量和抑郁症治疗结果的影响。
设计、设置和参与者:我们对考虑使用抗抑郁药治疗的中度至重度抑郁症成年人进行了一项整群随机试验。明尼苏达州和威斯康星州的10个农村、郊区和城市初级保健机构被随机分配为使用或不使用DMC决策辅助工具治疗抑郁症。
抑郁症药物选择,一系列卡片,每张卡片突出显示现有选项对患者重要问题的影响,供面对面会诊时使用。
通过患者知识和参与决策情况判断的决策质量、患者和临床医生的决策舒适度(决策冲突量表)和满意度、会诊时长、药物依从性、抑郁症状以及抑郁症患者健康问卷(PHQ-9)。
我们招募了117名临床医生和301名患者(67%为女性;平均[标准差]年龄,44[15]岁;平均[标准差]PHQ-9评分,15[4])进入试验。与常规护理(UC)相比,使用DMC显著提高了患者的决策舒适度(DMC为80%,UC为75%;P = 0.02)、知识水平(DMC为65%,UC为56%;P = 0.03)、满意度(风险比[RR],根据满意度领域从1.25[P = 0.81]到RR为2.4[P = 0.002])以及参与度(DMC为47%,UC为33%;P<0.001)。它还提高了临床医生的决策舒适度(DMC为80%,UC为68%;P < 0.001)和满意度(RR为1.64;P = 0.02)。两组在会诊时长、药物依从性或抑郁症控制改善方面没有差异。
DMC决策辅助工具帮助初级保健临床医生和中度至重度抑郁症患者共同选择抗抑郁药,在不延长就诊时间的情况下改善了决策过程。另一方面,DMC对药物依从性或抑郁症治疗结果没有明显影响。通过将比较疗效转化为以患者为中心的护理,使用DMC提高了抑郁症患者的初级保健质量。
clinicaltrials.gov标识符:NCT01502891。